| Bioactivity | Mazorelvimab (SYN023) is a combination of CTB011 and CTB012 humanized monoclonal antibodies cocktail against rabies virus (RABV). Mezagitamab binds to non-overlapping epitopes on RABV glycoprotein (G). Mezagitamab has potential application in the prevention of rabies[1][2]. |
| Invitro | Mazorelvimab (0.01-100 µg/mL) 以剂量依赖性方式对 CVS-11 感染的 BSR 细胞显示出细胞毒性，但对未感染的 BSR 细胞无影响[1]。 |
| In Vivo | Mazorelvimab (0.03-1.0 mg/kg；肌肉注射；单剂量) 以剂量依赖性方式提高了被狂犬病毒 (RABV) 感染的仓鼠的存活率[1]。Mazorelvimab (0.003-1mg/kg；肌肉注射；单剂量) 以剂量依赖性方式提高 RABV 感染的仓鼠的存活率。Mazorelvimab (0.003-0.03 mg/kg) 对未感染病毒的叙利亚仓鼠血清 RVNA 水平无显著干扰[2]。Mazorelvimab (0.03-1 mg/kg；肌肉注射；单剂量) 对感染 RABV (BD06) 的比格犬具有保护作用[2]。 Animal Model: |
| Name | Mazorelvimab |
| CAS | 2419087-89-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chao TY, et al. SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006133. [2]. Chao TY, et al. In Vivo Efficacy of SYN023, an Anti-Rabies Monoclonal Antibody Cocktail, in Post-Exposure Prophylaxis Animal Models. Trop Med Infect Dis. 2020 Feb 21;5(1):31. |